Literature DB >> 15301543

Substitutions of glutamate 110 and 111 in the middle helix 4 of human apolipoprotein A-I (apoA-I) by alanine affect the structure and in vitro functions of apoA-I and induce severe hypertriglyceridemia in apoA-I-deficient mice.

Angeliki Chroni1, Horng-Yuan Kan, Kyriakos E Kypreos, Irina N Gorshkova, Adelina Shkodrani, Vassilis I Zannis.   

Abstract

Hypertriglyceridemia is a common pathological condition in humans of mostly unknown etiology. Here we report induction of dyslipidemia characterized by severe hypertriglyceridemia as a result of point mutations in human apolipoprotein A-I (apoA-I). Adenovirus-mediated gene transfer in apoA-I-deficient (apoA-I(-)(/)(-)) mice showed that mice expressing an apoA-I[E110A/E111A] mutant had comparable hepatic mRNA levels with WT controls but greatly increased plasma triglyceride and elevated plasma cholesterol levels. In addition, they had decreased apoE and apoCII levels and increased apoB48 levels in very low-density lipoprotein (VLDL)/intermediate-density lipoprotein (IDL). Fast protein liquid chromatography (FPLC) analysis of plasma showed that most of cholesterol and approximately 15% of the mutant apoA-I were distributed in the VLDL and IDL regions and all the triglycerides in the VLDL region. Hypertriglyceridemia was corrected by coinfection of mice with recombinant adenoviruses expressing the mutant apoA-I and human lipoprotein lipase. Physicochemical studies indicated that the apoA-I mutation decreased the alpha-helical content, the stability, and the unfolding cooperativity of both lipid-free and lipid-bound apoA-I. In vitro functional analyses showed that reconstituted HDL (rHDL) particles containing the mutant apoA-I had 53% of scavenger receptor class B type I (SR-BI)-mediated cholesterol efflux capacity and 37% capacity to activate lecithin:cholesterol acyltransferase (LCAT) as compared to the WT control. The mutant lipid-free apoA-I had normal capacity to promote ATP-binding cassette transporter A1 (ABCA1)-dependent cholesterol efflux. The findings indicate that subtle structural alterations in apoA-I may alter the stability and functions of apoA-I and high-density lipoprotein (HDL) and may cause hypertriglyceridemia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15301543     DOI: 10.1021/bi049782p

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  25 in total

1.  High-density lipoprotein attenuates Th1 and th17 autoimmune responses by modulating dendritic cell maturation and function.

Authors:  Ioanna Tiniakou; Elias Drakos; Vaios Sinatkas; Miranda Van Eck; Vassilis I Zannis; Dimitrios Boumpas; Panayotis Verginis; Dimitris Kardassis
Journal:  J Immunol       Date:  2015-04-13       Impact factor: 5.422

2.  Enhanced binding of apolipoprotein A-I variants associated with hypertriglyceridemia to triglyceride-rich particles.

Authors:  Irina N Gorshkova; David Atkinson
Journal:  Biochemistry       Date:  2011-02-20       Impact factor: 3.162

3.  Structure and stability of apolipoprotein a-I in solution and in discoidal high-density lipoprotein probed by double charge ablation and deletion mutation.

Authors:  Irina N Gorshkova; Tong Liu; Horng-Yuan Kan; Angeliki Chroni; Vassilis I Zannis; David Atkinson
Journal:  Biochemistry       Date:  2006-01-31       Impact factor: 3.162

4.  Role of the hydrophobic and charged residues in the 218-226 region of apoA-I in the biogenesis of HDL.

Authors:  Panagiotis Fotakis; Andreas K Kateifides; Christina Gkolfinopoulou; Dimitra Georgiadou; Melissa Beck; Katharina Gründler; Angeliki Chroni; Efstratios Stratikos; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2013-08-29       Impact factor: 5.922

Review 5.  Lipid-free Apolipoprotein A-I Structure: Insights into HDL Formation and Atherosclerosis Development.

Authors:  Xiaohu Mei; David Atkinson
Journal:  Arch Med Res       Date:  2015-06-03       Impact factor: 2.235

6.  Significance of the hydrophobic residues 225-230 of apoA-I for the biogenesis of HDL.

Authors:  Panagiotis Fotakis; Ioanna Tiniakou; Andreas K Kateifides; Christina Gkolfinopoulou; Angeliki Chroni; Efstratios Stratikos; Vassilis I Zannis; Dimitris Kardassis
Journal:  J Lipid Res       Date:  2013-10-12       Impact factor: 5.922

7.  Domains of apoE4 required for the biogenesis of apoE-containing HDL.

Authors:  Alexander M Vezeridis; Angeliki Chroni; Vassilis I Zannis
Journal:  Ann Med       Date:  2011-06       Impact factor: 4.709

8.  A thumbwheel mechanism for APOA1 activation of LCAT activity in HDL.

Authors:  Allison L Cooke; Jamie Morris; John T Melchior; Scott E Street; W Gray Jerome; Rong Huang; Andrew B Herr; Loren E Smith; Jere P Segrest; Alan T Remaley; Amy S Shah; Thomas B Thompson; W Sean Davidson
Journal:  J Lipid Res       Date:  2018-05-17       Impact factor: 5.922

9.  Sequence-specific apolipoprotein A-I effects on lecithin:cholesterol acyltransferase activity.

Authors:  Alexander D Dergunov
Journal:  Mol Cell Biochem       Date:  2013-03-21       Impact factor: 3.396

10.  Biophysical properties of apolipoprotein E4 variants: implications in molecular mechanisms of correction of hypertriglyceridemia.

Authors:  Irina N Gorshkova; Kyriakos E Kypreos; Donald L Gantz; Vassilis I Zannis; David Atkinson
Journal:  Biochemistry       Date:  2008-11-25       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.